CN101977626A - 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途 - Google Patents

丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途 Download PDF

Info

Publication number
CN101977626A
CN101977626A CN2009801099736A CN200980109973A CN101977626A CN 101977626 A CN101977626 A CN 101977626A CN 2009801099736 A CN2009801099736 A CN 2009801099736A CN 200980109973 A CN200980109973 A CN 200980109973A CN 101977626 A CN101977626 A CN 101977626A
Authority
CN
China
Prior art keywords
serine protease
inhibitor
protease inhibitor
recombinant
kallikrein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801099736A
Other languages
English (en)
Chinese (zh)
Inventor
D·德佩尔特
C·昆丁
A·霍夫纳尼安
C·德雷松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Dermadis SA
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Dermadis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Dermadis SA filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to CN201910841916.2A priority Critical patent/CN110522905A/zh
Publication of CN101977626A publication Critical patent/CN101977626A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Birds (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
CN2009801099736A 2008-01-21 2009-01-21 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途 Pending CN101977626A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910841916.2A CN110522905A (zh) 2008-01-21 2009-01-21 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2238608P 2008-01-21 2008-01-21
US61/022,386 2008-01-21
US657608P 2008-01-22 2008-01-22
US61/006,576 2008-01-22
PCT/IB2009/000089 WO2009093119A2 (en) 2008-01-21 2009-01-21 Use of serine protease inhibitors in the treatment of skin diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910841916.2A Division CN110522905A (zh) 2008-01-21 2009-01-21 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途

Publications (1)

Publication Number Publication Date
CN101977626A true CN101977626A (zh) 2011-02-16

Family

ID=40901490

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801099736A Pending CN101977626A (zh) 2008-01-21 2009-01-21 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途
CN201910841916.2A Pending CN110522905A (zh) 2008-01-21 2009-01-21 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910841916.2A Pending CN110522905A (zh) 2008-01-21 2009-01-21 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途

Country Status (8)

Country Link
US (3) US20110130338A1 (https=)
EP (1) EP2244728B1 (https=)
JP (2) JP5615184B2 (https=)
CN (2) CN101977626A (https=)
AU (1) AU2009207394B2 (https=)
BR (1) BRPI0906167A2 (https=)
CA (1) CA2712512C (https=)
WO (1) WO2009093119A2 (https=)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014043861A1 (en) * 2012-09-19 2014-03-27 Yeou-Ping Tsao Use of pedf-derived polypeptides for preventing and/or ameliorating skin aging
CN106478812A (zh) * 2016-10-21 2017-03-08 沈阳药科大学 丝氨酸蛋白酶抑制剂‑3及其功能、制备方法和应用
CN106573155A (zh) * 2014-02-26 2017-04-19 鲁玛治疗公司 紫外光疗设备和方法
CN110114463A (zh) * 2016-11-23 2019-08-09 阿尔尼拉姆医药品有限公司 丝胺酸蛋白酶抑制剂A1 iRNA组合物及其使用方法
CN110330563A (zh) * 2013-12-13 2019-10-15 剑桥实业有限公司 用于出血性疾病治疗的修饰的丝氨酸蛋白酶抑制剂
CN110536691A (zh) * 2017-04-21 2019-12-03 豪夫迈·罗氏有限公司 Klk5拮抗剂治疗疾病的用途
CN111050850A (zh) * 2017-06-16 2020-04-21 阿兹特拉公司 用于用表达lekti的重组微生物治疗内瑟顿综合征的组合物和方法
CN114867865A (zh) * 2019-11-21 2022-08-05 密执安大学评议会 中性粒细胞弹性蛋白酶活性的多肽抑制剂及其用途
CN117084936A (zh) * 2023-09-22 2023-11-21 南京盛德生物科技研究院有限公司 多萜类化合物作为激肽释放酶抑制剂在化妆品中的应用
WO2026021603A1 (zh) * 2024-07-25 2026-01-29 吉林大学第一医院 Serpina3蛋白变异体或其编码序列以及它们的应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101977626A (zh) 2008-01-21 2011-02-16 德莫迪斯公司 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途
AU2010222537B2 (en) * 2009-03-10 2016-06-30 Med Discovery Sa Use of serine protease inhibitors in the treatment of neutropenia
CN103502337B (zh) 2011-12-09 2015-11-25 迈图高新材料日本合同公司 硅橡胶发泡体用组合物、硅橡胶发泡体的制造方法和硅橡胶发泡体
US10550154B2 (en) 2012-08-08 2020-02-04 Daiichi Sankyo Company, Limited Peptide library and use thereof
KR101437408B1 (ko) 2012-11-05 2014-09-05 동아대학교 산학협력단 플라스민 및 엘라스타아제 저해 활성을 갖는 산왕거미 유래의 쿠니츠 타입 세린 프로테아제 저해 단백질 및 이를 유효성분으로 포함하는 염증 억제 및 항섬유소용해용 조성물
US10807805B2 (en) 2013-05-17 2020-10-20 Intelligrated Headquarters, Llc Robotic carton unloader
EP2996973B1 (en) 2013-05-17 2019-01-30 Intelligrated Headquarters LLC Robotic carton unloader
WO2015114144A1 (en) * 2014-02-03 2015-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of netherton syndrome
TW201619605A (zh) * 2014-10-24 2016-06-01 Shiseido Co Ltd 用以改善起因於角質層剝離之抑制或促進之肌膚狀態的美容方法及評價方法
MA40998A (fr) 2014-11-21 2017-09-26 Ophirex Inc Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
US10597235B2 (en) 2016-10-20 2020-03-24 Intelligrated Headquarters, Llc Carton unloader tool for jam recovery
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
AU2019346549B2 (en) * 2018-09-24 2024-09-12 Krystal Biotech, Inc. Compositions and methods for the treatment of Netherton Syndrome
PH12022550646A1 (en) 2019-09-18 2023-04-03 Genentech Inc Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
US20230099101A1 (en) * 2020-03-06 2023-03-30 The Regents Of The University Of Michigan Serine protease inhibitors for suppressing or preventing anaphylactic reaction
CN112315897A (zh) * 2020-11-04 2021-02-05 深圳前海鹰岗生物科技有限公司 一种抑制细胞炎症反应释放治疗痛风急性发作的聚合物微针及制备方法
WO2023141125A2 (en) * 2022-01-18 2023-07-27 The Regents Of The University Of California Method of inhibiting degrading protease activity in aging
JP7820193B2 (ja) * 2022-03-04 2026-02-25 株式会社ナリス化粧品 角層剥離改善剤
WO2024159008A1 (en) * 2023-01-25 2024-08-02 Quoin Pharmaceuticals, Inc. Combination treatment for netherton syndrome

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079336A (en) * 1989-06-23 1992-01-07 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
US5252725A (en) * 1989-06-23 1993-10-12 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
DE4214215A1 (de) * 1992-04-30 1993-11-04 Behringwerke Ag Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen
AUPP508798A0 (en) * 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
JP2003502071A (ja) * 1999-06-18 2003-01-21 ブジャーナソン・ヨーン・ブラーギ 魚類セリンプロティナーゼ及びそれらの薬品及び化粧品への利用
US7105172B1 (en) * 1999-11-18 2006-09-12 Bolla John D Treatment of rosacea
JP2004535758A (ja) * 2000-11-14 2004-12-02 ブリストル−マイヤーズ　スクイブ　カンパニー リンパ様細胞ｌｓｉ−０１から分泌される新規なヒトセルピンをコードするポリヌクレオチド
US20040097481A1 (en) * 2002-11-20 2004-05-20 Benjamin Levinson Water-soluble mesoporphyrin compounds and methods of preparation
CA2506839A1 (en) * 2002-11-20 2004-06-03 Prometic Biosciences, Inc. Composition and method for treating inflammatory diseases using protease inhibitors
JP4754478B2 (ja) * 2003-04-04 2011-08-24 ユニバーシティ オブ ローザンヌ プロテアーゼに対するインヒビタータンパク質およびその利用
WO2005117955A1 (en) * 2004-05-19 2005-12-15 Arriva Pharmaceuticals, Inc. Treatment of atopic dermatitis with unglycosylated alpha one-antitrypsin
EP1666075A1 (en) * 2004-10-04 2006-06-07 Switch Biotech Aktiengesellschaft Wound dressing compositions, especially for delivery of protease inhibitors
WO2006090282A2 (en) * 2005-02-28 2006-08-31 Universite De Lausanne Recombinant inhibitor proteins of an hk14 protease and use thereof
GB0525999D0 (en) * 2005-12-21 2006-02-01 Ares Trading Sa Novel members of the kazal family of serine protease inhibitors
BRPI0813230A2 (pt) * 2007-06-28 2014-12-23 Novartis Ag Moduladores de calicreína 7
WO2009024528A1 (en) * 2007-08-17 2009-02-26 Novartis Ag Use of cyclic depsipeptides to inhibit kallikrein 7
CN101977626A (zh) * 2008-01-21 2011-02-16 德莫迪斯公司 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104903346A (zh) * 2012-09-19 2015-09-09 财团法人台湾基督长老教会马偕纪念社会事业基金会马偕纪念医院 Pedf衍生的多肽在预防和/或缓和皮肤老化中的用途
US9815878B2 (en) 2012-09-19 2017-11-14 Mackay Memorial Hospital Use of PEDF-derived polypeptides for preventing and/or ameliorating skin aging
CN104903346B (zh) * 2012-09-19 2019-04-09 财团法人台湾基督长老教会马偕纪念社会事业基金会马偕纪念医院 Pedf衍生的多肽在预防和/或缓和皮肤老化中的用途
WO2014043861A1 (en) * 2012-09-19 2014-03-27 Yeou-Ping Tsao Use of pedf-derived polypeptides for preventing and/or ameliorating skin aging
CN110330563A (zh) * 2013-12-13 2019-10-15 剑桥实业有限公司 用于出血性疾病治疗的修饰的丝氨酸蛋白酶抑制剂
CN110330563B (zh) * 2013-12-13 2024-03-29 剑桥实业有限公司 用于出血性疾病治疗的修饰的丝氨酸蛋白酶抑制剂
CN106573155A (zh) * 2014-02-26 2017-04-19 鲁玛治疗公司 紫外光疗设备和方法
CN106478812B (zh) * 2016-10-21 2020-11-20 沈阳药科大学 丝氨酸蛋白酶抑制剂-3及其功能、制备方法和应用
CN106478812A (zh) * 2016-10-21 2017-03-08 沈阳药科大学 丝氨酸蛋白酶抑制剂‑3及其功能、制备方法和应用
CN110114463A (zh) * 2016-11-23 2019-08-09 阿尔尼拉姆医药品有限公司 丝胺酸蛋白酶抑制剂A1 iRNA组合物及其使用方法
CN110536691A (zh) * 2017-04-21 2019-12-03 豪夫迈·罗氏有限公司 Klk5拮抗剂治疗疾病的用途
CN111050850A (zh) * 2017-06-16 2020-04-21 阿兹特拉公司 用于用表达lekti的重组微生物治疗内瑟顿综合征的组合物和方法
CN114867865A (zh) * 2019-11-21 2022-08-05 密执安大学评议会 中性粒细胞弹性蛋白酶活性的多肽抑制剂及其用途
CN117084936A (zh) * 2023-09-22 2023-11-21 南京盛德生物科技研究院有限公司 多萜类化合物作为激肽释放酶抑制剂在化妆品中的应用
WO2026021603A1 (zh) * 2024-07-25 2026-01-29 吉林大学第一医院 Serpina3蛋白变异体或其编码序列以及它们的应用

Also Published As

Publication number Publication date
BRPI0906167A2 (en) 2018-05-22
JP5615184B2 (ja) 2014-10-29
EP2244728A2 (en) 2010-11-03
JP2014240389A (ja) 2014-12-25
WO2009093119A3 (en) 2009-11-26
JP5891266B2 (ja) 2016-03-22
US11793864B2 (en) 2023-10-24
CN110522905A (zh) 2019-12-03
CA2712512A1 (en) 2009-07-30
AU2009207394B2 (en) 2015-01-22
EP2244728B1 (en) 2016-08-31
CA2712512C (en) 2018-08-28
US20110130338A1 (en) 2011-06-02
WO2009093119A2 (en) 2009-07-30
US20140341881A1 (en) 2014-11-20
US20190183989A1 (en) 2019-06-20
AU2009207394A1 (en) 2009-07-30
JP2011511766A (ja) 2011-04-14

Similar Documents

Publication Publication Date Title
CN101977626A (zh) 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途
US20110104179A1 (en) Protease inhibitory peptides
US20140288007A1 (en) Gingipain inhibitory propeptides
JP4585342B2 (ja) 不全角化を抑制する物質のスクリーニング方法、同方法によりスクリーニングされた物質及び不全角化を抑制する方法
KR101296367B1 (ko) 프로테아제 억제 단백질 및 그 이용
US9642898B2 (en) Use of serine protease inhibitors in the treatment of neutropenia
HK1151236A (en) Use of serine protease inhibitors in the treatment of skin diseases
ES2604215T3 (es) Uso de inhibidores de serina proteasas en el tratamiento de enfermedades de la piel
Diamandis et al. Induction of Complement C3a Receptor
Valueva et al. A novel human leukocyte elastase inhibitor from duck egg white

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1151236

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110216

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1151236

Country of ref document: HK